Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3Phase EARLY_PHASE1 1Phase 4 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Skin Neoplasms 3Kasabach-Merritt Syndrome 2Kaposiform Hemangioendothelioma 2Waldenstrom Macroglobulinemia 1Renal Transplant Patients at High-risk for Skin Cancer 1Refractory Solid Tumors 1Peutz-Jeghers Syndrome 1Neoplasms, Plasma Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leiomyoma 1Hereditary Sensory and Autonomic Neuropathies 1Hemangioma 1Angiomyolipoma 1

Interventions

fludarabine phosphate 1fludarabine 1Thiotepa 1Sirolimus 1Radiotherapy 1Prednisone 1Influenza Vaccines 1Fluzone High-Dose 1Filgrastim 1Everolimus 1Cyclophosphamide 1Busulfan 1Antilymphocyte Serum 113-valent pneumococcal vaccine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Neoplasms, Plasma Cell × Sirolimus × Clear all
NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Dana-Farber Cancer Institute

Phase 4 Not yet recruiting
80 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡